Sengenics
Sengenics is a Singapore-based functional proteomics company that uses its proprietary KREX™ protein folding technology to identify novel biomarkers, serving pharmaceutical, biotech, and academic translational research customers.
- Company typePrivate
- Founded1996
- HeadquartersSingapore, Singapore
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Sengenics does
Sengenics is a Singapore-based functional proteomics company founded in 1996, operating with 51-100 employees as a privately held for-profit entity. The company's stated focus is leveraging its KREX™ protein folding technology for the identification of novel biomarkers, positioning it in the translational proteomics segment serving pharmaceutical, biotechnology, and academic research customers seeking high-fidelity antibody-based protein profiling.
The company's core asset is the KREX™ protein folding platform, described in source material as a technology that preserves correctly folded protein structures to enable biologically relevant antibody interactions, supporting applications in biomarker discovery, disease biology, drug screening, vaccine development, and the study of post-translational modifications. Leadership comprises CEO Jerry Williamson, Co-founder and Board Director Arif Anwar, and VP of Market and Business Development Fredrik Sundberg. A 2019 funding event tied to Cancer Research UK signals early institutional engagement in oncology-adjacent biomarker work.
The business model is not explicitly disclosed in the input data; no pricing structure, customer segments, revenue mechanics, or distribution channels are characterized. The firm appears to operate as a specialized tools and services provider in the functional proteomics niche, but the absence of revenue figures, named customers, product/service catalog, and go-to-market detail in the source material limits deeper characterization. It is worth noting that much of the detailed technology content in the source input pertains to SomaLogic's KREX™ platform rather than Sengenics' implementation, which constrains the specificity of this description.
Sengenics firmographics
Firmographics- Name
- Sengenics
- Website
- https://sengenics.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Sengenics is a Singapore-based functional proteomics company that uses its proprietary KREX™ protein folding technology to identify novel biomarkers, serving pharmaceutical, biotech, and academic translational research customers.
- Ownership category
- akta.pro rank
Sengenics industry classification
Industry- Product category
- Functional Proteomics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Sengenics is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Markets served
Sengenics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Sengenics product offering
Product offeringCore offering
Sengenics is a functional proteomics company that leverages its proprietary KREX™ protein folding technology to enable high-plex antibody profiling and identification of novel biomarkers. The technology preserves correctly folded protein structures recognized by 90% of antibodies, supporting applications including biomarker discovery, disease biology research, drug screening, vaccine development, and post-translational modification studies for pharmaceutical, biotech, and academic research customers.
Product overview
No product information for Sengenics was found in the provided source data. The available sources contain information about SomaLogic's KREX™ Technology (antibody profiling platform) and industry news about the omics lab services market, but no direct references to Sengenics products, services, or technology offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- KREX™ Technology Platform
Companies that use Sengenics
Customer profileIdeal customer profiles2 records
Sengenics technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sengenics partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
Sengenics competitors and assessment
Company assessmentBroad incumbents
- Abcam: Abcam (acquired by Danaher) is a major antibody and proteomics reagents provider serving academic and pharmaceutical researchers globally. Overlaps with Sengenics as a supplier of protein research tools used in biomarker discovery workflows.
- Bio-Rad Laboratories: Bio-Rad is a broad life science tools incumbent offering protein analysis instruments, Bio-Plex multiplex assay systems, and reagents. Overlaps with Sengenics in proteomics workflow tools sold to research and clinical research customers.
- Cell Signaling Technology: Cell Signaling Technology is a leading provider of antibodies and antibody-based proteomics reagents used in academic and pharma research. Overlaps with Sengenics in antibody-based protein detection workflows.
Direct peers
- Olink Holding: Olink (acquired by Thermo Fisher Scientific in 2024) is the leading direct competitor in high-plex protein biomarker discovery using proximity extension assay (PEA) technology. Both Sengenics and Olink sell proteomics platforms to biopharma and academic researchers for biomarker discovery and translational applications.
- Standard BioTools (formerly Fluidigm): Standard BioTools provides mass cytometry and multiplexed protein profiling instruments used in translational research and biomarker discovery. Competes with Sengenics in proteomics research tools for pharma and academic customers.
- Meso Scale Diagnostics: Meso Scale Diagnostics (MSD) offers multiplexed immunoassay platforms for biomarker discovery and pharma research. MSD competes with Sengenics in high-multiplex antibody-based protein profiling for translational research applications.
- SomaLogic (now Illumina): SomaLogic, acquired by Illumina, operates the SomaScan platform using SOMAmer/aptamer reagents to measure thousands of proteins simultaneously. Both companies compete in high-plex proteomics for biomarker discovery, with overlapping pharmaceutical and academic customer bases.
Emerging players
- Quanterix: Quanterix commercializes Simoa single-molecule array technology for ultra-sensitive protein detection. While focused more on low-plex ultra-sensitive assays, Quanterix overlaps with Sengenics in neurology and biomarker discovery research markets.
- IsoPlexis: IsoPlexis (now part of Bruker) provides single-cell proteomics platforms using antibody barcoding. Competes with Sengenics in functional proteomics and immune profiling applications for pharma and academic research.
- Seer: Seer offers the Proteograph platform for unbiased, deep proteomics using nanoparticle-based enrichment. Competes with Sengenics in biomarker discovery applications, particularly in large-scale population proteomics studies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Sengenics social profiles
Digital presenceSengenics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sengenics leadership team
Management profileNumber of profiles
Profiles3 records
Sengenics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sengenics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sengenics
What does Sengenics do?
Sengenics is a functional proteomics company that leverages its proprietary KREX™ protein folding technology to enable high-plex antibody profiling and identification of novel biomarkers. The technology preserves correctly folded protein structures recognized by 90% of antibodies, supporting applications including biomarker discovery, disease biology research, drug screening, vaccine development, and post-translational modification studies for pharmaceutical, biotech, and academic research customers.
Is Sengenics a public or private company?
Sengenics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sengenics founded?
Sengenics was founded in 1996. It employs 51 to 100 people.
Where is Sengenics based?
Sengenics is headquartered in Singapore, Singapore, in the Asia region.
Who are Sengenics's main competitors?
Broad incumbents on record are Abcam, Bio-Rad Laboratories and Cell Signaling Technology. Direct peers are Olink Holding, Standard BioTools (formerly Fluidigm), Meso Scale Diagnostics and SomaLogic (now Illumina). Emerging players are Quanterix, IsoPlexis and Seer.
Does Sengenics have an API?
No public API is recorded for Sengenics.
What industry is Sengenics in?
Sengenics's product category is Functional Proteomics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 2835.